Targeting protein-protein interaction interfaces in COVID-19 drug discovery

Targeting protein-protein interaction interfaces in COVID-19 drug discovery

Blog Article

To date, the COVID-19 pandemic has claimed over 1 million human lives, infected another 50 million individuals and wreaked havoc on the global economy.The crisis has spurred the ongoing development of drugs targeting its etiological agent, the SARS-CoV-2.Targeting relevant protein-protein interaction interfaces (PPIIs) is a viable paradigm for the design of antiviral drugs and enriches the targetable chemical space by read more providing alternative targets for drug discovery.

In this review, we will provide a comprehensive overview of the theory, methods and applications of PPII-targeted drug development towards COVID-19 based on recent literature.We will also highlight novel developments, such as the successful use of non-native protein-protein interactions as targets for antiviral drug screening.We hope that this review may serve as an entry point for those interested in applying PPIIs towards COVID-19 drug discovery teal horse blanket and speed up drug development against the pandemic.